Helix Acquisition Corp IIHLXB
HLXB
About: Helix Acquisition Corp II is a Blank check company.
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
8% more capital invested
Capital invested by funds: $173M [Q4 2024] → $186M (+$13.6M) [Q1 2025]
0.22% more ownership
Funds ownership: 86.97% [Q4 2024] → 87.19% (+0.22%) [Q1 2025]
3% less funds holding
Funds holding: 32 [Q4 2024] → 31 (-1) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for HLXB.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination
Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“ Helix ”) (Nasdaq: HLXB), a special purpose acquisition company (“ SPAC ”) sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (“ BBOT ”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the “ Registration Statement ”), filed by Helix and BBOT, relating to the previously-announced business combination among Helix, BBOT, and the other parties thereto (the “ Business Combination ”), has been declared effective by the U.S. Securities and Exchange Commission (“ SEC ”).
Neutral
Business Wire
5 months ago
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
SOUTH SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB) (“Helix”), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, today announced that they have entered into a definitive business combination a.
Neutral
Business Wire
1 year ago
Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Helix Acquisition Corp. II (Nasdaq: HLXB) (the “Company”) announced today that on February 13, 2024 it closed the initial public offering of 18,400,000 Class A ordinary shares which includes 2,400,000 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The offering was priced at $10.00 per share resulting in gross proceeds of $184,000,000, before deducting underwriting discounts and commissions and other offering expenses payable.
Charts implemented using Lightweight Charts™